AlloMek, founded in 2011, is a privately held orphan disease-focused company, developing therapeutics for catastrophic cardiomyopathy (based on discovery by Dr. Worman’s group at Columbia University) and congenital muscular disease for which there are no disease-modifying treatments, caused by LMNA genetic mutations (laminopathies). In parallel, the Company plans to pursue other MEK-associated orphan diseases, specifically, Neurofibromatosis Type 1 and Noonan Syndrome. AlloMek’s lead compound, CIP-137401, is a unique, proprietary, macrocyclic small molecule MEK kinase inhibitor, it has demonstrated powerful proof of concept (POC) in a well-established mouse model of Emery-Dreifuss muscular dystrophy caused by LMNA gene mutations. CIP-137401 can potentially be used as a single agent and in combination with other treatment options to enhance clinical response.allomek.com
Woodbridge, CT, USA
Inaccurate data? Flag it here.
Open jobs at AlloMek
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.